BC
ARCT icon

Belmont Capital’s Arcturus Therapeutics ARCT Stock Holding History

Belmont Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$520K Hold
40,000
– – 0.08% 70
2025
Q1 		$424K Hold
40,000
– – 0.08% 77
2024
Q4 		$679K Hold
40,000
– – 0.11% 42
2024
Q3 		$928K Hold
40,000
– – 0.15% 47
2024
Q2 		$974K Hold
40,000
– – 0.18% 47
2024
Q1 		$1.35M Buy
+40,000
New +$1.42M 0.37% 30

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Belmont Capital's ARCT Position: Q2 2025 in Review

Belmont Capital held its Arcturus Therapeutics (ARCT) position steady in Q2 2025 at 40,000 shares worth $520K. The position accounts for 0.08% of the portfolio, ranked #70.

Belmont Capital first reported a position in ARCT in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.35M in Q1 2024. 143 funds tracked by Wall St. Rank hold ARCT as of Q2 2025.

  • Belmont Capital held 40,000 shares of Arcturus Therapeutics worth $520K as of Q2 2025.
  • Belmont Capital left its Arcturus Therapeutics share count unchanged in Q2 2025.
  • Arcturus Therapeutics made up 0.08% of Belmont Capital's portfolio in Q2 2025, its #70 holding.
  • Belmont Capital first reported a position in Arcturus Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Belmont Capital's Arcturus Therapeutics position peaked at $1.35M in Q1 2024.
  • 143 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2025.

Based on Belmont Capital's 13F filing for Q2 2025, filed 12 Aug 2025.